Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company’s business segments include, diabetes and ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Weight loss leader Novo ... Nordisk in the recent months and whether there's still a Buy case for it. A key reason for NVO's drop is the disappointing trial results for its obesity and diabetes ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report ... based largely on booming sales of their diabetes and obesity products. With their surges over the last ...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers. It needs next generation innovation and growth in emerging markets to keep ahead of competitors ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

The small molecule helped patients with type 2 diabetes improve their blood sugar ... At the same time, American depository receipts of rival Novo Nordisk plunged nearly 8% yesterday, as investors ...

Updated recommendations from an international group of diabetes experts aim to inform diabetes educators about best practices ...

This all suggests that orforglipron is useful for both treating diabetes and weight loss -- and with no needles required. Image source: Getty Images. Lilly notes that the ACHIEVE-1 study was only ...